Management of HRS-CKD
Patients with hepatorenal syndrome and chronic kidney disease (HRS-CKD) should be promptly referred for liver transplantation evaluation, as this is the only definitive treatment, while avoiding vasoconstrictor therapy which is not indicated for HRS-CKD. 1
Understanding HRS-CKD
HRS-CKD is defined as an estimated glomerular filtration rate <60 mL/min/1.73 m² for ≥3 months in the absence of other potential causes of kidney disease in patients with cirrhosis and ascites 1. This represents a distinct entity from HRS-AKI and requires fundamentally different management.
Key Management Principles
What NOT to Do
Vasoconstrictors (terlipressin, norepinephrine, midodrine/octreotide) plus albumin are NOT recommended for HRS-CKD 2. These therapies are only indicated for HRS-AKI Stage 2 or greater. The evidence shows that while vasoconstrictors may temporarily improve renal function in HRS-CKD (formerly HRS type 2), recurrence after treatment withdrawal is the norm, and there is no proven impact on long-term clinical outcomes 2.
Primary Management Strategy
Immediate liver transplantation referral is the cornerstone of management 3. All patients with HRS-CKD who are potential transplant candidates should be referred without delay.
Transplantation Considerations
- Simultaneous liver-kidney transplantation (SLK) should be considered for patients meeting updated Organ Procurement and Transplantation Network criteria 1
- Patients with prolonged pre-transplant renal replacement therapy >6 weeks should be evaluated for SLK 3
- Post-transplant data show that 72.7-78.9% of HRS patients develop CKD stage ≥III after liver transplantation alone, with outcomes similar to patients with pre-existing CKD 4
Supportive Care Measures
While awaiting transplantation:
- Avoid nephrotoxic agents: Discontinue NSAIDs, aminoglycosides, and contrast agents 1
- Careful diuretic management: Monitor closely to prevent volume depletion while managing ascites 1
- Avoid large-volume paracentesis without albumin replacement (use 6-8g albumin per liter removed) 1
- Aggressive infection surveillance and treatment: Infection is a major precipitant of acute decompensation 3
Renal Replacement Therapy
RRT in HRS-CKD should be individualized 1:
- Only consider RRT for transplant candidates as a bridge to liver transplantation 1
- Indications include: severe electrolyte disturbances, refractory acidosis, volume overload, or symptomatic uremia 2, 5
- Continuous RRT is preferred over intermittent hemodialysis for hemodynamic stability 2, 5
- Do NOT initiate RRT in non-transplant candidates with HRS-CKD - mortality rates are extremely high without transplantation 5
Non-Transplant Candidates
For patients who are not liver transplant candidates:
- Palliative care referral is appropriate 3
- Focus on symptom management and quality of life
- Avoid futile interventions including RRT 5
Critical Pitfalls to Avoid
Do not treat HRS-CKD with vasoconstrictors - this wastes resources and exposes patients to ischemic complications without meaningful benefit 2
Do not delay transplant evaluation - HRS-CKD represents advanced liver disease with poor prognosis; repeated episodes of AKI increase CKD progression risk 1
Monitor for acute-on-chronic deterioration - patients with HRS-CKD can develop superimposed HRS-AKI, which would then require vasoconstrictor therapy 1
Avoid excessive albumin - while albumin is beneficial in HRS-AKI treatment, indiscriminate use risks pulmonary edema 1
Prognosis
The evidence is sobering: HRS-CKD carries a 7-fold increase in morbidity and mortality compared to cirrhotic patients without AKI 1. Even after successful liver transplantation, the majority of HRS patients develop significant CKD, with pre-transplant eGFR <46.4 mL/min/1.73 m² predicting post-transplant CKD stage ≥III 4. This underscores the importance of early preventative strategies and consideration of SLK in appropriate candidates.